OncoHealth的动态

What is Antibody-drug conjugates (ADCs) ? This is an important modality in cancer treatment, and article by UT HEALTH SCIENCE CENTER HOUSTON authors - Kyoji Tsuchikama, Yasuaki Anami is a great summary of the ADC in oncology. ? Link: https://rdcu.be/dABYy Innovative ADC Formats: The development of bispecific ADCs, probody-drug conjugates, and dual-drug ADCs showcases the potential to tackle clinical challenges and improve patient outcomes. Component Enhancements: Advancements in antibody, linker, and payload designs enhance the efficacy and safety of ADCs. Personalized Treatment Approaches: The significance of patient stratification and biomarker identification for optimizing the benefits of ADC therapies. This research underscores the importance of innovation in ADC development, promising a brighter future for cancer treatment. #CancerResearch #Innovation #PersonalizedMedicine #drugdevelopment

?? Boudicca Dx believes that CDx development should be streamlined whenever possible. ?? There are too many biomarker conundrums to tackle & too much to learn about why patients respond and do not respond to targeted therapies. ?? Read our recent white paper with a proposed framework for oncology targeted molecular therapies. ?? Applying this framework may enable you to pursue a multi-dimensional oncology biomarker approach ("hallmarks of cancer") to learn more about your therapy's MOA and provide insights on clinical responses (or lack of responses). https://lnkd.in/eBETWQ3W

Innovations in Cancer Diagnostics to be revealed during ASCO 2024. With the arrival of the 2024 American Society of Clinical Oncology Annual Meeting, excitement mounts for the forthcoming data unveilings by top players in oncology diagnostics. Key industry leaders like Predicine, Natera, Guardant Health, Precede Biosciences, GRAIL, Exact Sciences, 燃石医学 Burning Rock Biotech, SAGA Diagnostics, HaploX Biotechnology, Personalis, Inc., Foresight, Illumina, and others are poised to present their latest clinical study findings. These presentations are poised to spotlight notable advancements and breakthroughs in cancer diagnostics, heralding a new era in the battle against cancer. Get detailed insights: https://lnkd.in/gwcB4m6m #ASCO2024 #OncologyDiagnostics #CancerResearch #ClinicalStudy #Predicine #Natera #GuardantHealth #MedicalInnovations #CancerDetection #DataPresentations #CancerInnovations #FightAgainstCancer

Marking #WorldCancerDay earlier this week, we have released a special edition blog that unveils 5 mind-blowing breakthroughs in cancer research and treatment. Demonstrating our capability in global cancer trials, click here: https://lnkd.in/eiR4rh5V to learn more and access our case study on successful end-to-end clinical trials, risk management, pharmacokinetic monitoring support, and US FDA audits for a global pharma's study on renal cell carcinoma. Discover how we ensured the successful completion of 2 US FDA site audits without any 483 findings and with regulatory approval for the study received within 45 days! #Oncology #OncologyResearch #ClinicalTrials #Carcinoma

This #BreastCancerAwarenessMonth, we’re highlighting how Flatiron’s #1000publications have improved treatment options for men with breast cancer ?? Published in American Society for Clinical Pharmacology & Therapeutics, Flatiron’s RWD on men with HR+, HER2- breast cancer supported the FDA’s expansion of palbociclib, a CDK inhibitor that dramatically changed the way breast cancer is treated. An extremely rare patient population, traditional standards of prospective clinical evidence would be nearly impossible to secure regulatory approval for male patients with breast cancer. Through use of high-quality RWD, this research brought a valuable therapeutic advancement to a rare patient group in need. Learn more about why this matters: https://spkl.io/6041fPrHT

Anti-CD47 drug market This innovative class of therapies is gaining momentum for its potential to enhance cancer treatment by enabling the immune system to effectively target and destroy tumor cells. As research progresses, we're seeing promising clinical results and increasing investments in this area. Stay tuned as we explore the impact of these breakthroughs on patient outcomes and the future of oncology! Get more on: https://lnkd.in/d3Rq9Tjr #CancerResearch #Immunotherapy #HealthcareInnovation AntiCD47 #Immunotherapy #CancerTreatment #Oncology #PrecisionMedicine #Biotech #PharmaInnovation #ClinicalTrials #CancerResearch #TargetedTherapy #DrugDevelopment #HealthcareInnovation

https://lnkd.in/eKtrTrYV Takeaway: The U.S. spent $99 billion on both oral and clinician-administered cancer therapies in 2023, according to a?report?published in April by analytics firm IQVIA. As cancer drug prices continue to increase, spending is projected to grow.

Oncologists recently gathered at #ASCO2024 to discuss the latest in cancer research, with a major focus on biomarkers and antibody-drug conjugates (ADCs). Highlights included groundbreaking trial data for small molecules like Lorbrena and Tagrisso, emphasizing the effectiveness of targeted biomarker therapies. Notable advancements in biomarker technologies and individualized neoantigen therapies were also showcased, alongside challenges in ADC efficacy and safety. Future discussions will explore new biomarker detection methods and multitarget ADCs to enhance specificity and reduce side effects. To read the full CRA Insights by Aaron E., click here: https://crai.news/a88 #CRALifeSciences

?? Join Quest Diagnostics' upcoming webinar on the evolving role of diagnostic labs in biomarker-driven oncology therapies. Dr. Yuri Fesko MD will delve into the transformative role of diagnostic labs in the rapidly advancing field of precision medicine. Attendees will learn how biomarkers like HER2 revolutionize cancer treatment with targeted therapies, streamline drug development, and enhance approval rates. The webinar will also cover the shift of diagnostic labs from service providers to proactive oncology partners, their role in clinical trials and companion diagnostics, and how precision medicine is reshaping oncology through real-world examples and case studies. ?? REGISTER HERE: https://buff.ly/4dwenpo #Cancer #PrecisionMedicine #Oncology #Biomarkers #ClinicalData #OncologyTrials #Diagnostics #TherapeuticAreas #OncologyDrugDevelopment

We are excited to invite you to our upcoming webinar: “Antibody?Drug?Conjugates: A Novel Targeted Approach to Cancer Therapy”. The use of ADC's in clinical trials and approved treatments continues to rise at an ever-increasing pace. Hear from industry experts around the successes, advancements, and future direction of ADCs with a focus on precision oncology. https://lnkd.in/dg7bGhy2